Loading clinical trials...
Loading clinical trials...
The purpose of this study is to identify at least 1 dose of Daclatasvir, that when combined with peginterferon-alfa (PegIFNα) and ribavirin (RBV) for the treatment of chronically infected HCV genotype...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Bristol-Myers Squibb
NCT01866930 · Chronic Hepatitis C Infection
NCT02190305 · HIV Infections, Hepatitis B Infections, and more
NCT02333292 · Chronic Hepatitis C Infection
NCT00991289 · HIV Infection, Hepatitis C Infection
NCT02582632 · Hepatitis C Infection, Hepatitis C Virus
Local Institution
Chiba, Chiba
Local Institution
Kurume-Shi, Fukuoka
Local Institution
Okayama, Okayama-ken
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions